Phenotyping

#Assays #Drug discovery #Imaging #Live cell analysis #Macrophages #Phenotyping #Technical Note

Optimise macrophage assays and boost immunology research

A new free resource from Lonza is now available entitled ‘Optimising macrophage polarisation and phagocytosis assays‘. Download this Technical Note to learn: Streamlined Macrophage Workflow: Transform cryopreserved or PBMC-derived monocytes into M1 or M2 macrophages using a reproducible, high-throughput protocol. Comprehensive Validation: Confirm phenotype and function with live-cell imaging… Read More

#News

#Assays #Drug discovery #Imaging #Live cell analysis #Macrophages #Phenotyping

Optimising macrophage polarisation and phagocytosis assays

Download this Technical Note to learn: Streamlined Macrophage Workflow: Transform cryopreserved or PBMC-derived monocytes into M1 or M2 macrophages using a reproducible, high-throughput protocol. Comprehensive Validation: Confirm phenotype and function with live-cell imaging and phagocytosis assays for application-ready results. Accelerated Research: Enhance drug discovery, immunotoxicology, and screening workflows with both… Read More

#Resources

Human cell
#High throughput screening #iPSC #Live cell analysis #Organoids #Phenotyping #Stem cells #Webinar

Register now: Discover a robust method for organoid development

The value of stem cells in laboratory and clinical research has been clearly demonstrated through numerous studies, showcasing their potential as models for a wide range of diseases and therapeutic developments. The inherent flexibility of stem cells allows for the development of various tissue types from a single,… Read More

Webinar date:
Supported by Sartorius
#News

Pluripotent stem cells
#High throughput screening #iPSC #Live cell analysis #Organoids #Phenotyping #Stem cells #Webinar

Webinar: Generate human hepatic organoids from iPSCs

The value of stem cells in laboratory and clinical research has been clearly demonstrated through numerous studies, showcasing their potential as models for a wide range of diseases and therapeutic developments. The inherent flexibility of stem cells allows for the development of various tissue types from a single,… Read More

Webinar date:
Supported by Sartorius
#News

Stem cells
#High throughput screening #iPSC #Live cell analysis #Organoids #Phenotyping #Stem cells #Webinar

Webinar: Differentiate iPSCs into hepatic lineage cells and organoids

The value of stem cells in laboratory and clinical research has been clearly demonstrated through numerous studies, showcasing their potential as models for a wide range of diseases and therapeutic developments. The inherent flexibility of stem cells allows for the development of various tissue types from a single,… Read More

Webinar date:
Supported by Sartorius
#News

Organoid
#High throughput screening #iPSC #Live cell analysis #Organoids #Phenotyping #Stem cells #Webinar

Register now: Learn streamlined hepatic differentiation techniques

The value of stem cells in laboratory and clinical research has been clearly demonstrated through numerous studies, showcasing their potential as models for a wide range of diseases and therapeutic developments. The inherent flexibility of stem cells allows for the development of various tissue types from a single,… Read More

Webinar date:
Supported by Sartorius
#News

Organoid
#High throughput screening #iPSC #Live cell analysis #Organoids #Phenotyping #Stem cells

From iPSCs to Organoids: Streamlined Hepatic Differentiation Techniques

In this webinar, we describe the process of differentiating human iPSCs into hepatocytes using three distinct media types, each supplemented with specific growth factors and cytokines at key stages of differentiation. This method provides a relatively straightforward approach to producing mature hepatic cells, enabling the generation of human hepatic organoids… Read More

Webinar date:
Supported by Sartorius
#Webinars

Cytometry
#Drug development #Drug discovery #Mass cytometry #Phenotyping #Preclinical development

Digital Article: Immunophenotyping for targeted drug discovery

A new digital article is now available to download entitled ‘A comprehensive approach to immunophenotyping for targeted drug discovery and development’.  With high costs of therapeutic development, success relies on optimising preclinical and early clinical studies. Download this content-rich digital article to read… Read More

#News

#Drug development #Drug discovery #Mass cytometry #Phenotyping #Preclinical development

A comprehensive approach to immunophenotyping for targeted drug discovery and development

With high costs of therapeutic development, success relies on optimising preclinical and early clinical studies. Download this content-rich digital article to read about considerations for implementing and standardising high-dimensional immune profiling methods into drug development programs. Learn about different applications that demonstrate the robustness and reproducibility of a mass cytometry-based… Read More

#Resources

Remyelination
#Acquisition #CNS #Drug discovery #Pheno Therapeutics #Phenomics #Phenotyping

Pheno Therapeutics buys rights to potential remyelination drug

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology… Read More

#Business & Investment #News

Drug screening in laboratory
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Collaboration #Drug targets #High throughput screening #Partnership #Phenotyping #PhoreMost #ThinkCyte

New research collaboration to advance AI based drug discovery

PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).  The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry. … Read More

#News

#App note #Genetic profiling #Human disease models #Huntington's disease #Phenotyping

Using disease models to accelerate Huntington’s disease research

Currently, no effective cure or treatment for Huntington’s disease exists. To accelerate Huntington’s disease research and drug discovery, researchers need access to physiologically relevant human disease models that recapitulate patient phenotypes, in combination with more advanced methods to understand the underlying mechanisms of the disease. Download this… Read More

#News

#App note #Genetic profiling #Human disease models #Huntington's disease #Phenotyping

Characterising the phenotype of an isogenic, human iPSC-derived Huntington’s disease model by MEA

Currently, no effective cure or treatment for Huntington’s disease exists. To accelerate Huntington’s disease research and drug discovery, researchers need access to physiologically relevant human disease models that recapitulate patient phenotypes, in combination with more advanced methods to understand the underlying mechanisms of the disease. In this App Note you… Read More

#App Notes #Intelligence #Resources

Man using microscope in lab
#Collaboration #Phenotyping #PhoreMost #Protein binders #Therapeutic targets

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration. Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration… Read More

#Business & Investment #News

#Biosciences #Funding #Liver disease #Phenotyping

$30 million financing for RNA therapies for chronic liver diseases 

Ochre Bio, a company developing therapies for liver health challenges, has closed $30 million in Series A financing, which will be used to translate the insights from their discovery research into RNA-based drug candidates, and then test these in human livers at their recently launched ‘Liver ICUs’ across the… Read More

#News